Views

CrossRef citations to date

Altmetric

Special Section: Estimands, Design and Analysis of Clinical Trials with Time-to-Event Outcomes

Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials

Yuan-Li Shena Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MDCorrespondence[email protected]

Xin Wanga Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Mushti Sirishaa Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Flora Mulkeya Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Jiaxi Zhoua Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Xin Gaoa Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Lijun Zhanga Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Thomas Gwisea Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Shenghui Tanga Office of Biostatistics, Office of Translational Science, FDA, Silver Spring, MD

Marc Theoretb Oncology Center for Excellence (OCE), FDA, Silver Spring, MD

Richard Pazdurb Oncology Center for Excellence (OCE), FDA, Silver Spring, MD

Rajeshwari Sridharab Oncology Center for Excellence (OCE), FDA, Silver Spring, MD

show all

Abstract

The Cross-PhRMA working group has proposed using the MaxCombo test in place of the log-rank test to evaluate treatment differences based on time-to-event endpoints, particularly if nonproportional hazards are expected. Despite demonstrating improved power and overall Type I error control, concerns about using this test for inferential purposes remain. We evaluated the MaxCombo test by reanalyzing data from six cancer clinical trials submitted to the U.S. Food and Drug Administration. Interpretation of the MaxCombo test results is not clear when the Kaplan–Meier curves crossed or had early separation. In addition, we note difficulty in interpretation of the results from the MaxCombo test when the source cause of deviation from proportionality of the survival distributions is due to underlying factors such as differential treatment effect of subgroups or intercurrent events. We illustrate these concerns based on the case examples.

Keywords:

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials

Information for

Open access

Opportunities

Help and information

Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials

Abstract

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature